Mesoblast likely to raise cash after FDA setbackThe stem cell-focused biotech has been rebuffed again by the US Food and Drug Administration, hitting its shareholder hard, including billionaire Melbourne investor Alex Waislitz.
Source: https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fcompanies%2Fmesoblast-raises-an-extra-605m-still-has-alex-waislitzs-support-who-concedes-its-been-a-long-journey%2Fnews-story%2Fc8be3e464d46c6016dcca96b261b68ee&memtype=anonymous&mode=premium&v21=dynamic-high-test-score&V21spcbehaviour=appendend
Mesoblast likely to raise cash after FDA setbackThe stem...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |